Sernova (Sernova) Change In Receivables : $0.04 Mil (TTM As of Jan. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Change In Receivables?

Sernova's change in receivables for the quarter that ended in Jan. 2024 was $0.27 Mil. It means Sernova's Accounts Receivable declined by $0.27 Mil from Oct. 2023 to Jan. 2024 .

Sernova's change in receivables for the fiscal year that ended in Oct. 2023 was $0.17 Mil. It means Sernova's Accounts Receivable declined by $0.17 Mil from Oct. 2022 to Oct. 2023 .

Sernova's Accounts Receivable for the quarter that ended in Jan. 2024 was $0.77 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sernova's liquidation value for the three months ended in Jan. 2024 was $1.18 Mil.

Sernova Change In Receivables Historical Data

The historical data trend for Sernova's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Change In Receivables Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Change In Receivables

Get a 7-Day Free Trial

0.08

0.01

-0.07

-0.14

0.17

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Receivables	Get a 7-Day Free Trial															0.40	-0.08	-0.03	-0.12	0.27

Sernova Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

Sernova (OTCPK:SEOVF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sernova's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.767	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Sernova's accounts receivable are only considered to be worth 75% of book value:

Sernova's liquidation value for the quarter that ended in Jan. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.585	-	10.98	+	0.75 * 0.767	+	0.5 * 0
=	1.18

Sernova Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sernova's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (Sernova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (OTCPK:SEOVF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.